Binding of CYP2C9 with Diverse Drugs and its Implications for Metabolic Mechanism

E-ISSN： 1875-6638|5|3|263-270

ISSN： 1573-4064

Source： Medicinal Chemistry, Vol.5, Iss.3, 2009-05, pp. : 263-270

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effect of Genetic Polymorphisms in Cytochrome P450 (CYP) 2C9 and CYP2C8 on the Pharmacokinetics of Oral Antidiabetic Drugs: Clinical Relevance

By Kirchheiner Julia Roots Ivar Goldammer Mark Rosenkranz Bernd

Clinical Pharmacokinetics, Vol. 44, Iss. 12, 2005-01 ,pp. : 1209-1225

Adis International

Access to resources Recommend Favorite

Inhibitory effects of H-antihistamines on CYP2D6- and CYP2C9-mediated drug metabolic reactions in human liver microsomes

By He Nu Zhang Wen-Qi Shockley Dolores Edeki Timi

European Journal of Clinical Pharmacology, Vol. 57, Iss. 12, 2002-02 ,pp. : 847-851

Springer Publishing Company

Access to resources Recommend Favorite

Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo

By Wennerholm Agneta Nordmark Anna Pihlsgård Maria Mahindi Margarita Bertilsson Leif Gustafsson Lars

European Journal of Clinical Pharmacology, Vol. 62, Iss. 7, 2006-07 ,pp. : 539-546

Springer Publishing Company

Access to resources Recommend Favorite

The Pharmacogenetics of CYP2C9 and CYP2C19: Ethnic Variation and Clinical Significance

Current Clinical Pharmacology, Vol. 2, Iss. 1, 2007-01 ,pp. : 93-109

Bentham Science Publishers

Access to resources Recommend Favorite

CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population

By Scott Stuart A Edelmann Lisa Kornreich Ruth Erazo Monica Desnick Robert J

Pharmacogenomics, Vol. 8, Iss. 7, 2007-07 ,pp. : 721-730

Future Medicine

Access to resources Recommend Favorite